[ad_1]
The potential for psychedelic drugs such as psilocybin and mescaline to treat a range of mental and physical disorders has attracted intense research attention — and has become a topic of public fascination. But the move from research lab to the clinic throws up multiple challenges. Nature Outlook convened a panel of researchers and journalists to dig into the most tantalizing opportunities for these therapies, as well as some of the stickiest problems that face drug developers, mental-health therapists, regulators and patients.
[ad_2]
Source link